A double‐blind, placebo‐controlled trial of modafinil (200 mg/day) for methamphetamine dependence

Abstract

Modafinil demonstrated promise in reducing methamphetamine use in selected methamphetamine-dependent patients. The study findings support definitive trials of modafinil in larger multi-site trials.